| Abstrakt: |
A new report from Central South University in China provides insights into the clinical features, treatment, and outcomes of nivolumab-induced hemophagocytic lymphohistiocytosis (HLH). HLH is a rare and fatal immune-related event associated with nivolumab therapy. The study analyzed case reports and found that HLH developed in 24 patients, with fever being the most common symptom. Laboratory tests revealed various abnormalities, and bone marrow biopsy showed hemophagocytosis. Treatment with systemic steroids, tocilizumab, and anakinra showed positive results. The study emphasizes the importance of rapid diagnosis and appropriate treatment for HLH. [Extracted from the article] |
